Madhu Kumar

Tim Lugo

- Akari Therapeutics Plc entered into an **Ordinary Share Purchase Agreement** with White Lion Capital, LLC on **August 29, 2025**, allowing the company to sell up to **$25,000,000** in newly issued Ordinary Shares.  **[1541157_0001641172-25-026032_form8-k.htm:1]** **[1541157_0001641172-25-026032_ex10-1.htm:0]** 
- The agreement provides Akari Therapeutics Plc with the **right, but not the obligation**, to sell shares over a **Commitment Period** ending on the earlier of the full amount being purchased or **August 29, 2028**.  **[1541157_0001641172-25-026032_form8-k.htm:1]** 
- Sales under the agreement are contingent upon a **registration statement** covering the resale of the shares being declared effective by the SEC.  **[1541157_0001641172-25-026032_form8-k.htm:1]** 
- As consideration for the agreement, Akari Therapeutics Plc will pay a **document preparation fee of $15,000** and additional cash commitment fees based on aggregate purchase notices.  **[1541157_0001641172-25-026032_form8-k.htm:2]**

Akari Therapeutics (AKTX)